Tan Kin Lian says he joined Chinese Communist Party in jest, gets query from MHAOn Dec. 6, the Berkeley Chamber of Commerce marked the grand opening of the fifth Berkeley Community Resource Hub, located at the Tri-Community Center, 1708 Poplar Hill Drive in Cross. These Hubs represent the Berkeley Chamber’s commitment to strengthening rural communities by providing essential resources such as broadband internet, telehealth access, educational tools and workforce training opportunities. “It’s an effort to give every citizen in Berkeley County an opportunity,” said Elaine Morgan, CEO of the Berkeley County Chamber of Commerce. “Because of the barriers, there were two Berkeley Counties; now there is inclusion.” Each Hub has been outfitted with cutting-edge technology, including free high-speed Wi-Fi, telehealth computers, Chromebooks and other equipment to serve the community’s diverse needs. The hubs are meant to narrow the chasms of the haves and have-nots in the county that is expanding and modernizing in some places while others are left behind. It’s a statewide problem. “I am here to tell you the digital divide in South Carolina is going to be solved in the next year or two,” said Tom Allen, the chief technology officer for the South Carolina Office of Regulatory Staff, the agency tasked with solving the digital divide in the state. “This technology is moving into areas that may have never had it before. People have never used this technology. They may not have the skills and education. South Carolina has acquired an additional $ 12.8 million with the legislature’s support to come in and provide funding for digital literacy programs and educational programs.” The hubs are bringing those rural communities into the fold. So far, rural communities in Cainhoy and Alvin have been connected, and this past October, the Wassmassaw community was also plugged into the Wi-Fi network. The site at 1023 Queenie Road serves the Sheep Island and Long Ridge areas. The initiative depends on an existing brick-and-mortar building. All of the sites are long overdue, but it is happening, and elected officials in rural areas are happy to share this with their constituents, who now have an open door to better help themselves. “When we learn how to come together, stay together and work together, we can make things happen in our community,” said Berkeley County Council member Caldwell Pinckney. “We talk about politicians not doing this for you or not doing that for you. Nobody will do more for you than what you can do for yourselves.”Swinney and Brown at memorial service for ‘giant of a man’ Alex SalmondShoppers can get 'powerful' £250 Dyson vacuum for £122 if they don't wait for Black Friday
Nvidia's stock is down over 10% as Trump talks up tariffs‘Malcolm in the Middle’ Reboot Set Ahead of Show’s 25th Anniversary
Kam Jones scored 20 points and dished with 10 assists to lead the No. 10 Marquette Golden Eagles to a 94-62 victory over the visiting Western Carolina on Saturday afternoon in Milwaukee. Jones added six rebounds for Marquette (8-0), which is off to its best start since winning 10 straight to begin the 2011-12 campaign that ended with a Sweet 16 appearance. Ben Gold added 12 points, while Stevie Mitchell scored 10 and had three steals. David Joplin, Caedin Hamilton and Royce Parham each netted nine points for the Golden Eagles. The Catamounts (2-4) were led by Bernard Pelote's 13 points and eight boards. Jamar Livingston chipped in 10 points and CJ Hyland bundled five points with five rebounds and six assists. Marquette controlled most of the game, thanks largely to 51.4 percent shooting and 21 takeaways. The Golden Eagles built a 16-point lead in the first half before Western Carolina clawed within 37-28 with 3:55 left. Marquette responded with a 12-2 run to take a 49-30 advantage into the break, its largest lead of the game to that point. The game quickly got out of hand from there, with the Golden Eagles eventually scoring 11 straight points to push its lead to 81-45 with 7:15 remaining. Marquette finished with 26 points off of Catamount turnovers and hit 14 of 40 shots (35.0 percent) from 3-point range. The win wasn't all smooth sailing for the Golden Eagles, who lost backup guard Zaide Lowery to an apparent left knee injury. Lowery was helped off the court and into the locker room by his teammates with 1:36 left in the game. Saturday's game was a final tune-up for Marquette, which has three challenging games coming up against No. 5 Iowa State, No. 15 Wisconsin and Dayton before Big East conference play begins Dec. 18. --Field Level MediaBiden will decide on US Steel acquisition after influential panel fails to reach consensusNEW YORK — After missing last weekend’s loss to the Dolphins, Jets running back Breece Hall could return in Week 15. Hall (knee) is listed as questionable for Sunday’s game against the Jaguars. “He looks good right now,” Jets interim coach Jeff Ulbrich said on Friday afternoon. “So, it looks promising.” Hall injured his knee during the Jets’ Week 11 loss to the Colts. However, Hall played in the team’s next game against the Seahawks following the Jets’ bye week. While Hall could play on Sunday, the Jets will be without returner and running back Kene Nwangwu. After breaking his hand, Nwangwu will be placed on injured reserve and miss the rest of the season. Nwangwu was named the AFC Special Teams Player of the Week after the Jets’ Week 13 loss to the Seahawks. In that game, after being elevated from the practice squad, Nwangwu registered a 99-yard kick-return touchdown and forced a fumble on a separate kickoff return. “He brought such value as a returner,” Ulbrich said about Nwangwu. “To put him out there with a broken hand, that would be counterproductive for him and us as a team. “Unfortunately, it cuts the season short and what a bright light he was and what an amazing future I think he has in this league.” The Jets’ secondary could be limited against the Jaguars. Brandin Echols (shoulder) is doubtful, and D.J. Reed (groin) is questionable. Ulbrich is “hopeful” Reed can play against Jacksonville. “It’s something that’s lingered here and there,” Ulbrich said about Reed’s groin injury. “It got aggravated and it went away and it got aggravated again. “We are hopeful, but we will see how it goes. He has been a guy that, it has been sore on a Friday and been able to play on a Sunday multiple times this year. We will see how that goes.” Sauce Gardner, who missed last week’s game due to a hamstring injury, will play against the Jaguars. If Echols and Reed do not play, rookie Qwan’tez Stiggers will likely receive more playing time opposite Gardner. “I’m excited for him,” Ulbrich said about Stiggers. “If he gets an opportunity to play, I’m excited about what he can do. He has demonstrated great growth this season and he has elite ball skills. “If we gotta roll with Qwan’tez Stiggers, we are excited about that opportunity for him and for us.” ©2024 New York Daily News. Visit nydailynews.com . Distributed by Tribune Content Agency, LLC.
No. 10 Marquette remains undefeated with convincing win over Western CarolinaAKRON, Ohio (AP) — Nate Johnson scored 25 points to help Akron defeat Alabama State 97-78 on Sunday. Johnson added five rebounds for the Zips (4-2). Bowen Hardman scored 19 points, shooting 6 for 7 from beyond the arc. Isaiah Gray went 4 of 7 from the field to finish with 11 points. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get the latest sports news delivered right to your inbox six days a week.
NYC officials want answers from NYPD, FBI about disconcerting drone sightings
A cup of joe is part of Australian daily life. But while it's now a regular occurrence to fork out $6 for your flat white, it might be about to get even worse. This is because arabica beans have surged to their highest price in 27 years, as supply issues mount among producing nations, leaving suppliers, cafes and consumers to feel the pinch. Arabica coffee is the most widely consumed type of coffee in Australia and the world, making up 60 per cent of the world's coffee production. Robusta coffee beans account for the rest of commercial coffee production. The main differences between arabica and robusta are their flavour, caffeine content and where they are grown. Roy Greenfield is the director of coffee at Zest Specialty Coffee Roasters, a wholesale supplier helping source coffee for cafes and restaurants operating in the nation's self-proclaimed coffee capital, Melbourne. He's worried about the cost and the quality of beans in the future. "The reason why the coffee price is so high is because of a drought and a reduction in coffee stocks in Brazil and Vietnam," Greenfield said. "So the bigger thing that keeps me awake at night is whether I can actually still get the same quality of coffee from those countries." Prices for the arabica bean climbed to US$3.03 a pound (454g), passing $3 for the first time since 2011. Prices have soared by more than 60 per cent this year. This coffee costs $200. Enthusiasts say it's a 'small price to pay' The world's biggest coffee producer, Nestlé, says we can expect prices to keep rising. "Arabica prices are rising and are forecast to rise further in 2025 as high temperatures and limited rainfall are compromising the projected harvest in Brazil," Martin Brown, beverages general manager at Nestlé Oceania, said. The key global coffee producers around the world are Brazil (36 per cent), Vietnam (11 per cent) and Colombia (8 per cent). But as cost pressures press upwards, it's a balancing act that's testing Johnny Sandish's business in Melbourne's bustling Degraves St, Xpressomondo. "Well, we have no choice now. We're losing money. But we cannot put the price any higher otherwise we lose all the customers," Sandish said. Analysts predict arabica prices will need to keep rising in the incoming months to ensure global supply is maintained. Source: SBS News If we're serious about coffee, Greenfield says consumers should get comfortable with paying more. "We say we are the coffee capital of the world. Now's the time to actually invest in that — and that's not just us as a roaster or the cafe, but that's the consumer." "If every cafe in Melbourne put their price up by 50 cents tomorrow morning, that would create sustainability for the cafe owner, the roasters, all the way through to the farmers." Australians drink six billion cups of coffee each year. Here's one way to reuse the waste In a statement to SBS News, Nestlé said: "We are continuing to work to find ways to minimise passing on these costs, but we will not compromise on the quality and taste of our products, or the investment we make in our farmers and coffee growing communities." "We are also investing to help secure a long-term coffee future, including accelerating our transition to regenerative agriculture to help build greater climate resilient coffee crops, improve yields and further support our farmers." How much coffee does Australia drink? Coffee is part of the DNA in Australia, with 75 per cent of us enjoying at least one cuppa each day, according to figures from McCrindle Research. More than one in four Australians can't survive the day without their coffee, while more than four in five buy coffee from cafes each week. The shortages are expected to have worldwide impacts, especially among the world's biggest coffee drinkers. Australia is the 10th largest importer of coffee in the world, importing about 132,000 tonnes of coffee in 2022/23, according to research from ANZ. When it comes to consumption per capita, the US Department of Agriculture ranks Australia eleventh in the world, consuming the equivalent of 4.5kg each of ground coffee per year.deepblue4you Introduction It’s been over a year since I last covered Netgear, Inc. ( NASDAQ: NTGR ) , so I thought it would be a good time to see how its operations have developed since then. While performance continued to decline, the company’s Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.Trump’s lawyers rebuff DA’s idea for upholding his hush money conviction, calling it ‘absurd’
SAN DIEGO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Marqeta, Inc. (NASDAQ: MQ) securities between August 7, 2024 and November 4, 2024. Marqeta creates digital payment technology for innovation leaders. For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Marqeta, Inc. (MQ) Failed to Disclose the Impact of Regulatory Scrutiny on its Business Prospects According to the complaint, during the class period, defendants failed to disclose that Marqeta understated the regulatory challenges affecting its business outlook and therefore, would have to cut its guidance for the fourth quarter of 2024. The complaint alleges that on November 4, 2024, Marqeta announced third quarter 2024 financial results and revised its fourth quarter projections to "reflect[] several changes that became apparent over the last few months with regards to the heightened scrutiny of the banking environment and specific customer program changes." The complaint further alleges that Marqeta's CEO and CFO actually knew of the heightened regulatory scrutiny affecting the Company's business from the beginning of the year, which they revealed in connection with the November 4 announcement. On this news, Marqeta’s stock price fell $2.53 per share, or 42.5%, to close at $3.42 per share on November 5, 2024. What Now : You may be eligible to participate in the class action against Marqeta, Inc. Shareholders who want to serve as lead plaintiff for the class must submit their application to the court by February 7, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here . All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Marqeta, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/53e69218-456a-4e86-81b7-b14619b1f825
TORONTO — Broad-based gains led Canada's main stock index to close higher in the shortened Christmas Eve trading session while U.S. stock markets also rose. The S&P/TSX composite index ended up 97.84 points at 24,846.82. In New York, the Dow Jones industrial average was up 390.08 points at 43,297.03. The S&P 500 index was up 65.97 points at 6,040.04, while the Nasdaq composite was up 266.24 points at 20,031.13. The Canadian dollar traded for 69.51 cents US compared with 69.47 cents US on Monday. The February crude oil contract was up 86 cents at US$70.10 per barrel and the February natural gas contract was up 16 cents at US$3.50 per mmBTU. The February gold contract ended up US$7.30 at US$2,635.50 an ounce and the March copper contract was up two cents at US$4.11 a pound. This report by The Canadian Press was first published Dec. 24, 2024. Companies in this story: (TSX:GSPTSE, TSX:CADUSD) The Canadian Press
Nayanthara And PV Sindhu Once BEAT Kamal Haasan And Ram Charan To Top Forbes India Celebrity 100
RNA Therapeutics Market Future Trends, New Opportunities, Business Growth, Share, Global Size, Demand, Key Segments And Forecast 12-13-2024 08:42 PM CET | Health & Medicine Press release from: ABNewswire The prominent players in the global RNA therapeutics market include Moderna, Inc. (US), Alnylam Pharmaceuticals, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), Ionis Pharmaceuticals, Inc. (US) Browse 135 market data Tables and 36 Figures spread through 171 Pages and in-depth TOC on "RNA Therapeutics Market by Product (Vaccines, Drugs), Type (mRNA Therapeutics, RNA Interference, Antisense Oligonucleotides), Indication (Infectious Diseases, Rare Genetic Diseases), End User (Hospitals & Clinics) - Global Forecast to 2028 RNA Therapeutics Market [ https://www.marketsandmarkets.com/Market-Reports/rna-therapeutics-market-235963408.html?utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr ] in terms of revenue was estimated to be worth $13.7 billion in 2023 and is poised to reach $18.0 billion by 2028, growing at a CAGR of 5.6% from 2023 to 2028 according to a new report by MarketsandMarkets Trademark . Growth in this market is largely driven by factors such as the increasing number of partnerships and collaborations among market players and RNA technology manufacturers, expanding modalities for RNA therapeutics, and the rising number of emergency use authorizations and approvals for COVID-19 booster vaccines. The emergence of small activating RNAs (saRNAs) and circular RNAs (circRNAs) has expanded the scope of RNA therapeutics. saRNAs are 21-nucleotide long double-stranded RNAs (dsRNAs) complementary to the promoter region of a targeted gene. They can upregulate gene expression, potentially correcting deficiencies associated with genetic disorders and re-activating tumor suppressor genes in multiple types of cancers. On the other hand, the discontinuation/recalls of RNA therapeutic products is expected to hinder market growth. Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=235963408 [ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=235963408&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr ] The vaccines segment accounted for the largest share of the RNA therapeutics market in 2022. Based on product, the RNA therapeutics market is segmented into drugs and vaccines. In 2022, vaccines represented majority of the market share and is anticipated to maintain this dominance throughout the forecast period. Two key vaccine products that have showcased majority revenue contribution in this segment, include Spikevax (Moderna, Inc.) and Comirnaty (Pfizer, Inc.) vaccines. Additionally, these COVID-19 vaccines showcased a considerable revenue growth between from 2021 and 2022. On the other hand, the recent recall/discontinuation of Spikevax (Moderna, Inc.) is anticipated to hinder the revenue growth post 2022. Increase in the development of innovative RNA medicine companies in the RNA therapeutics market has rendered it the fastest growing segment during the forecast period. The RNA interference (RNAi) therapeutics segment is expected to grow at the highest CAGR from 2023 to 2028. Based on the type, the RNA therapeutics market is segmented into RNA interference (RNAi) therapeutics, mRNA therapeutics, antisense oligonucleotide (ASO) therapeutics, and other therapeutics. Factors associated with RNA interference (RNAi) therapeutics such as precision and versatility have increased the potential of RNAi applications in personalized medicine and other clinical applications. On the other hand, the mRNA therapeutics segment accounted for the highest share in the global market in 2022 and is expected to maintain this trend through 2021-2028. The advantages of mRNA over DNA or proteins/peptides coupled with advent of novel vaccine and molecular entities are the key attributive reason to this dominance. The infectious diseases segment accounted for the largest share in the RNA therapeutics market in 2022. Based on the indication, the RNA therapeutics market is segmented into infectious diseases, rare genetic diseases/hereditary diseases, and other indications. The large share of the infectious diseases segment is a result of the rapid developments in RNA vaccine manufacturing capabilities for the treatment of infectious diseases along with the outbreak of COVID-19. Demand for mRNA vaccines grew significantly through 2021-2022, for immunization against SARS-COV-2 infection. Increase in the use of RNA-based therapeutics for the treatment of rare/genetic disorders contributes to the high share of hospitals & clinics. The RNA therapeutics market is segmented into hospitals and clinics and research settings. The growing use of RNA therapeutics across hospitals and clinics is driven by factors such as the increasing understanding and advancements of RNA-based therapeutics, the growing number of trends in personalized medicine, the increasing prevalence of chronic diseases, and the rising research investments by governments, private foundations, and industry stakeholders. Europe dominates the global RNA therapeutics market throughout the forecast period. The global RNA therapeutics market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. Europe leads the market for RNA vaccines, with highest share of revenue in this segment in 2022. North America has emerged as the fastest growing region from 2023 to 2028. The collective revenue share of Europe, across both RNA vaccines and RNA drugs is highest in 2022, and this is set to continue through the forecast period. Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=235963408 [ https://www.marketsandmarkets.com/requestsampleNew.asp?id=235963408&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr ] RNA Therapeutics Market Dynamics: Drivers: 1. Increasing partnerships and collaborations among market players and RNA technology manufacturers Restraints: 1. Discontinuation or recalls of RNA therapeutic products Opportunities: 1. Higher progress in the development of RNA aptamer-based therapeutics Challenge: 1. Rapid degradation by ubiquitous RNases in environment and tissues with strong immunogenicity of exogenous RNA Key Market Players: The prominent players in the global RNA therapeutics market include Moderna, Inc. (US), Alnylam Pharmaceuticals, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), Ionis Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Sanofi (France), Arrowhead Pharmaceuticals, Inc. (US), BioNtech SE (Germany), Orna Therapeutics (US), CRISPR Therapeutics (Switzerland), Silence Therapeutics (UK), Astellas Pharma Inc. (Japan), CureVac SE (Germany), Sirnaomics (US), Arcturus Therapeutics Inc. (US) and Arbutus Biopharma (US). Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=235963408 [ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=235963408&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr ] RNA Therapeutics Market Advantages: * Precision Medicine: RNA-based therapies can be tailored to target specific genetic mutations or disease pathways, allowing for personalized treatments that are more effective and have fewer side effects. * Speed of Development: The rapid development of RNA-based vaccines during the COVID-19 pandemic demonstrated the agility of this technology, which can potentially accelerate the response to emerging diseases and medical challenges. * Versatility: RNA can be engineered to address a wide range of diseases, including genetic disorders, cancer, infectious diseases, and rare diseases, making it a versatile platform for therapeutic development. * Reduced Off-Target Effects: Compared to traditional small molecule drugs, RNA therapies can have a higher degree of specificity, minimizing off-target effects on healthy cells and tissues. * Lower Manufacturing Costs: Advances in RNA synthesis and production techniques are driving down manufacturing costs, potentially making RNA therapies more accessible and affordable. * Targeting Undruggable Proteins: RNA therapeutics can target proteins that were previously considered "undruggable" with small molecules, expanding the range of potential drug targets. * Potential for Gene Editing: RNA-based therapies, such as CRISPR-Cas9, hold promise for precise gene editing and the treatment of genetic diseases at their root cause. * Immunomodulation: RNA molecules can be designed to stimulate or inhibit immune responses, making them valuable tools in the treatment of autoimmune diseases and for enhancing cancer immunotherapies. * Reduced Development Risk: The ability to rapidly iterate and optimize RNA therapies in preclinical and clinical stages can reduce the risks associated with drug development. * Therapeutic Innovation: RNA therapeutics represent a novel class of drugs that can complement existing treatment modalities, offering innovative solutions to unmet medical needs. Media Contact Company Name: MarketsandMarkets Trademark Research Private Ltd. Contact Person: Mr. Rohan Salgarkar Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=rna-therapeutics-market-future-trends-new-opportunities-business-growth-share-global-size-demand-key-segments-and-forecast ] Phone: 18886006441 Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 City: Florida State: Florida Country: United States Website: https://www.marketsandmarkets.com/Market-Reports/rna-therapeutics-market-235963408.html This release was published on openPR.
Rams at New Orleans Saints: Who has the edge?Say hello to your new coworker: Autonomous AI agents are coming to banks
It's getting harder to stay on the PGA Tour. Here's whyWild host the Predators after Spurgeon's 2-goal performanceMariah Carey, still fighting off the flu , has announced the cancellation of her weekend Christmas concerts in New Jersey and New York. “Newark and Belmont — I wish I had better news but unfortunately I’m still sick and have to cancel the shows tonight and on Sunday ,” she wrote on social media Friday morning, referring to her concerts at Newark’s Prudential Center and Elmont’s UBS Arena . “I’m really devastated about it and appreciate your support.” It doesn’t appear that either show will be rescheduled, though Ticketmaster assured fans they’d receive a full refund . The cancellations come two days after the Grammy winner told fans in Pittsburgh she’d come down with the flu just hours before that concert was scheduled to begin. As of Friday, the 55-year-old is still scheduled to perform at Brooklyn’s Barclays Center on Tuesday, wrapping up a 20-city trek of the annual Mariah Carey’s Christmas Time Tour. Fans online have largely been supportive of the ailing diva, who’s became synonymous with the holiday season thanks to her chart-topping 1994 hit “All I Want for Christmas Is You.” Carey last performed on Monday in North Carolina where her 13-year-old twins, Moroccan and Monroe, delivered flowers to her onstage as it was announced the Christmas classic had returned to No. 1 on the Billboard Hot 100 for the 15th time in 30 years. Netflix subscribers can see Carey on Christmas Day when a taped performance of the hitmaker airs before a pair of NFL games streaming live on the platform. Those wanting to see Carey perform live will have to wait until late January when she kicks off her “ Celebration of Mimi ” residency, which runs through Feb. 15 at the Park MGM in Las Vegas.Nathan Cleary’s bizarre diet change secret stuns fans